Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 366

1.

Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.

Cuisset T, Frere C, Quilici J, Morange PE, Mouret JP, Bali L, Moro PJ, Lambert M, Alessi MC, Bonnet JL.

JACC Cardiovasc Interv. 2008 Dec;1(6):649-53. doi: 10.1016/j.jcin.2008.08.018.

2.

The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.

Saw J, Densem C, Walsh S, Jokhi P, Starovoytov A, Fox R, Wong G, Buller C, Ricci D, Mancini GB, Fung A.

JACC Cardiovasc Interv. 2008 Dec;1(6):654-9. doi: 10.1016/j.jcin.2008.08.017.

3.

Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.

Konopka A, Spychalska J, Sitkiewicz D, Zdebska E, Pilichowska I, Piotrowski W, Stepińska J.

Am J Cardiovasc Drugs. 2007;7(6):433-9.

PMID:
18076210
4.

Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes.

Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S.

Clin Cardiol. 2008 Mar;31(3 Suppl 1):I2-9. doi: 10.1002/clc.20362. Review. Erratum in: Clin Cardiol. 2009 Feb;32(2):111.

5.

Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry.

El Ghannudi S, Ohlmann P, Meyer N, Wiesel ML, Radulescu B, Chauvin M, Bareiss P, Gachet C, Morel O.

JACC Cardiovasc Interv. 2010 Jun;3(6):648-56. doi: 10.1016/j.jcin.2010.03.003.

6.

Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).

Bromberg-Marin G, Marin-Neto JA, Parsons LS, Canto JG, Rogers WJ; National Registry of Myocardial Infarction-4.

Am J Cardiol. 2006 Nov 1;98(9):1125-31. Epub 2006 Aug 31.

PMID:
17056312
7.

Survival benefit with concomitant clopidogrel and glycoprotein IIb/IIIa inhibitor therapy at ad hoc percutaneous coronary intervention.

Gumina RJ, Yang EH, Sandhu GS, Prasad A, Bresnahan JF, Lennon RJ, Rihal CS, Holmes DR Jr, Singh M.

Mayo Clin Proc. 2008 Sep;83(9):995-1001. doi: 10.4065/83.9.995.

PMID:
18775199
8.

Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.

Aleil B, Jacquemin L, De Poli F, Zaehringer M, Collet JP, Montalescot G, Cazenave JP, Dickele MC, Monassier JP, Gachet C.

JACC Cardiovasc Interv. 2008 Dec;1(6):631-8. doi: 10.1016/j.jcin.2008.09.004.

9.

Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.

Claeys MJ, Van der Planken MG, Bosmans JM, Michiels JJ, Vertessen F, Van Der Goten P, Wuyts FL, Vrints CJ.

Eur Heart J. 2005 Mar;26(6):567-75. Epub 2004 Dec 16.

PMID:
15618034
10.

Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).

Chan AW, Moliterno DJ, Berger PB, Stone GW, DiBattiste PM, Yakubov SL, Sapp SK, Wolski K, Bhatt DL, Topol EJ; TARGET Investigators.

J Am Coll Cardiol. 2003 Oct 1;42(7):1188-95.

11.

Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.

Gawaz M, Ruf A, Neumann FJ, Pogátsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A.

Thromb Haemost. 1998 Dec;80(6):994-1001.

PMID:
9869173
12.

Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).

Park KW, Kang SH, Park JJ, Yang HM, Kang HJ, Koo BK, Park BE, Cha KS, Rhew JY, Jeon HK, Shin ES, Oh JH, Jeong MH, Kim S, Hwang KK, Yoon JH, Lee SY, Park TH, Moon KW, Kwon HM, Chae IH, Kim HS.

JACC Cardiovasc Interv. 2013 Sep;6(9):932-42. doi: 10.1016/j.jcin.2013.04.022.

13.

Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.

Pinkau T, Ndrepepa G, Kastrati A, Mann JF, Schulz S, Mehilli J, Schömig A.

Cardiology. 2008;111(4):247-53. doi: 10.1159/000127446. Epub 2008 Apr 23.

PMID:
18434733
14.

Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial).

Bonz AW, Lengenfelder B, Strotmann J, Held S, Turschner O, Harre K, Wacker C, Waller C, Kochsiek N, Meesmann M, Neyses L, Schanzenbächer P, Ertl G, Voelker W.

J Am Coll Cardiol. 2002 Aug 21;40(4):662-8.

15.
16.

Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.

Dery JP, Campbell ME, Mathias J, Pieper KS, Harrington RA, Madan M, Gibson CM, Tolleson TR, O'Shea JC, Tcheng JE; ESPRIT Investigators.

Catheter Cardiovasc Interv. 2007 Jul 1;70(1):43-50.

PMID:
17203469
17.

A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.

Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Bollwein H, Volmer C, Gawaz M, Berger PB, Schömig A; Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators.

N Engl J Med. 2004 Jan 15;350(3):232-8.

18.

Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.

Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PP, Schömig A; Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators.

Circulation. 2004 Dec 14;110(24):3627-35. Epub 2004 Nov 7.

19.

Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.

Bagur R, Bertrand OF, Rodés-Cabau J, Larose E, Rinfret S, Nguyen CM, Noel B, Larochellière RD, Poirier P, Costerousse O, Roy L.

Catheter Cardiovasc Interv. 2009 Dec 1;74(7):1010-6. doi: 10.1002/ccd.22235.

PMID:
19753635

Supplemental Content

Support Center